LnEASIX is a simple, robust, and continuous predictor of short- and long-term mortality in critically ill patients with ischemic stroke, and integrating this zero-cost biomarker with established intensive care scoring systems provides significant incremental value for early prognostic risk stratification.
A per-unit increase in lnEASIX was independently associated with elevated 28-day mortality risk in critically ill ischemic stroke patients.
lnEASIX was independently associated with all secondary mortality endpoints including in-hospital, 90-day, and 180-day mortality.
Restricted cubic spline analysis confirmed a strictly linear, monotonic dose-response relationship between lnEASIX and mortality.
lnEASIX demonstrated moderate standalone discriminative ability for mortality prediction, comparable to SOFA score.
Integrating lnEASIX with baseline SOFA score yielded significant incremental predictive value over SOFA alone.
Subgroup analysis showed that the prognostic impact of lnEASIX was markedly more pronounced in patients without pre-existing cancer.
The study analyzed 3063 critically ill ischemic stroke patients from the MIMIC-IV database using multiple analytical approaches.
This research suggests that a simple blood-test-based score called EASIX (Endothelial Activation and Stress Index), calculated from three routine laboratory values — lactate dehydrogenase (LDH), creatinine, and platelets — can predict the risk of death in critically ill patients who have suffered an ischemic stroke. Using data from over 3,000 stroke patients in a large hospital database (MIMIC-IV), the researchers found that higher lnEASIX scores at hospital admission were consistently linked to higher rates of death at 28 days, during hospitalization, and at 90 and 180 days after admission. Importantly, this relationship was linear, meaning that every incremental increase in the score was associated with progressively higher mortality risk. While lnEASIX performed similarly to the established SOFA score (a common ICU severity measure) on its own, the real benefit came from combining the two. Adding lnEASIX to SOFA meaningfully improved the ability to correctly classify patients by risk, as shown by significant improvements in reclassification and discrimination statistics. This matters because EASIX requires no additional testing — it is derived entirely from standard admission labs, making it a 'zero-cost' tool that can be immediately applied in any clinical setting. This research suggests that monitoring endothelial (blood vessel lining) dysfunction through EASIX could help clinicians identify high-risk stroke patients earlier and more accurately. The findings were broadly consistent across different patient subgroups, though patients with pre-existing cancer appeared to respond differently, which warrants further investigation. Overall, this study supports the potential use of lnEASIX as an easy-to-calculate complement to existing ICU scoring systems for stroke prognosis.
Bai W, Tao M, Li S, Shi W, Jiang K, Tian L. (2026). Prognostic Value of the Endothelial Activation and Stress Index (EASIX) in Critically Ill Patients With Ischemic Stroke: A MIMIC-IV Database Analysis.. Brain and behavior. https://doi.org/10.1002/brb3.71708